抗结核药物的研究进展  

Progress on antituberculosis drugs

作　　者：殷春阳 冷东雷 何仲贵[2] 

机构地区：[1]沈阳东陵药业股份有限公司,辽宁沈阳110161 [2]沈阳药科大学药学院,辽宁沈阳110016

出　　处：《沈阳药科大学学报》2015年第1期77-84,共8页Journal of Shenyang Pharmaceutical University

摘　　要：目的介绍抗结核药物的最新研究进展,对一线抗结核药物、二线抗结核药物和新型抗结核药物进行总结。方法参考近年来国内外文献48篇对抗结核药物进行了综述。结果一线抗结核药物和二线抗结核药物在临床上广泛使用,但由于耐多药结核杆菌的出现,使其不能达到有效控制结核病的目的,新型抗结核药物在未来几年有可能弥补现有抗结核药物的不足而广泛应用于临床。结论现有的抗结核药物还不能满足患者的需要,仍需开发更为有效的新型抗结核药物。Objective To introduce the progress of antituberculosis drugs and review first-line, second-line and new potential antituberculosis drugs. Method The progress of antituberculosis drugs were reviewed ac- cording to 48 published literatures. Results First-line and second-line antituberculosis drugs were widely used in clinic, but they still couldn＇ t effectively control tuberculosis because of the multidrug-resistant to tubercu- losis. In the coming years, new potential antituberculosis drugs might be supplements for the clinical use. Conclusions The existing antituberculosis drugs cannot meet the needs of patients; therefore, to develop more effective new antituberculosis drugs is needed.

关 键 词：结核病 一线抗结核药物 二线抗结核药物 新型抗结核药物 

分 类 号：R94[医药卫生—药剂学]